Equities research analysts forecast that ARMO Biosciences Inc (NASDAQ:ARMO) will post ($0.78) earnings per share for the current quarter, Zacks reports. Zero analysts have provided estimates for ARMO Biosciences’ earnings. The firm is scheduled to issue its next earnings report on Monday, January 1st.
On average, analysts expect that ARMO Biosciences will report full year earnings of ($3.77) per share for the current fiscal year, with EPS estimates ranging from ($5.14) to ($2.40). For the next year, analysts forecast that the firm will report earnings of ($2.27) per share, with EPS estimates ranging from ($2.83) to ($1.56). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow ARMO Biosciences.
ARMO has been the subject of a number of recent research reports. Jefferies Group initiated coverage on ARMO Biosciences in a report on Tuesday. They set a “buy” rating and a $61.00 price objective for the company. Robert W. Baird initiated coverage on ARMO Biosciences in a report on Tuesday. They set an “outperform” rating and a $67.00 price objective for the company. BMO Capital Markets initiated coverage on ARMO Biosciences in a report on Tuesday. They set an “outperform” rating and a $75.00 price objective for the company. Finally, Leerink Swann reissued a “market perform” rating on shares of ARMO Biosciences in a report on Tuesday.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3214817/zacks-analysts-expect-armo-biosciences-inc-armo-to-post-0-78-eps.html.
ARMO Biosciences Company Profile
ARMO Biosciences, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation. The Company’s platform molecule AM0010 is a pegylated form of recombinant human IL-10, which has immune stimulating effects that induce the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8+ T cells in cancer patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ARMO Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARMO Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.